- Home
- VTVT vs RNXT Comparison
VTVT vs RNXT Comparison
Compare VTVT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- RNXT
- Stock Information
- Founded
- VTVT 2015
- RNXT 2012
- Country
- VTVT United States
- RNXT United States
- Employees
- VTVT N/A
- RNXT N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- VTVT Health Care
- RNXT Health Care
- Exchange
- VTVT Nasdaq
- RNXT Nasdaq
- Market Cap
- VTVT 47.9M
- RNXT 44.6M
- IPO Year
- VTVT 2015
- RNXT 2021
- Fundamental
- Price
- VTVT $19.02
- RNXT $1.23
- Analyst Decision
- VTVT Strong Buy
- RNXT Strong Buy
- Analyst Count
- VTVT 2
- RNXT 2
- Target Price
- VTVT $35.50
- RNXT $7.50
- AVG Volume (30 Days)
- VTVT 2.9K
- RNXT 460.2K
- Earning Date
- VTVT 08-12-2025
- RNXT 08-14-2025
- Dividend Yield
- VTVT N/A
- RNXT N/A
- EPS Growth
- VTVT N/A
- RNXT N/A
- EPS
- VTVT N/A
- RNXT N/A
- Revenue
- VTVT $17,000.00
- RNXT $662,000.00
- Revenue This Year
- VTVT N/A
- RNXT $2,988.37
- Revenue Next Year
- VTVT N/A
- RNXT $300.60
- P/E Ratio
- VTVT N/A
- RNXT N/A
- Revenue Growth
- VTVT N/A
- RNXT N/A
- 52 Week Low
- VTVT $12.62
- RNXT $0.75
- 52 Week High
- VTVT $26.99
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- VTVT 70.74
- RNXT 58.40
- Support Level
- VTVT $15.79
- RNXT $1.06
- Resistance Level
- VTVT $21.01
- RNXT $1.27
- Average True Range (ATR)
- VTVT 0.84
- RNXT 0.08
- MACD
- VTVT 0.32
- RNXT 0.03
- Stochastic Oscillator
- VTVT 69.17
- RNXT 88.74
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.